Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 11 | 2025 | 469 | 4.960 |
Why?
|
| Antihypertensive Agents | 8 | 2024 | 155 | 3.070 |
Why?
|
| Atherosclerosis | 5 | 2025 | 52 | 2.600 |
Why?
|
| Cardiovascular Diseases | 6 | 2023 | 533 | 2.060 |
Why?
|
| Blood Pressure | 5 | 2025 | 275 | 1.980 |
Why?
|
| Atrial Fibrillation | 5 | 2023 | 172 | 1.880 |
Why?
|
| Diabetes Complications | 3 | 2021 | 106 | 1.650 |
Why?
|
| Arthritis, Rheumatoid | 3 | 2019 | 22 | 1.640 |
Why?
|
| Medication Adherence | 6 | 2020 | 239 | 1.620 |
Why?
|
| Humans | 40 | 2025 | 17376 | 1.450 |
Why?
|
| Stroke | 6 | 2023 | 310 | 1.430 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2023 | 185 | 1.390 |
Why?
|
| Aged | 25 | 2025 | 6129 | 1.390 |
Why?
|
| Delivery of Health Care, Integrated | 6 | 2025 | 537 | 1.370 |
Why?
|
| Retrospective Studies | 20 | 2025 | 2428 | 1.370 |
Why?
|
| Diabetes Mellitus | 4 | 2018 | 455 | 1.310 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2023 | 84 | 1.240 |
Why?
|
| Hypoglycemic Agents | 6 | 2025 | 251 | 1.240 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2025 | 666 | 1.240 |
Why?
|
| Middle Aged | 26 | 2025 | 7885 | 1.210 |
Why?
|
| Adult | 21 | 2025 | 7529 | 1.210 |
Why?
|
| Male | 28 | 2025 | 9843 | 1.170 |
Why?
|
| Warfarin | 3 | 2021 | 73 | 1.150 |
Why?
|
| Female | 27 | 2025 | 12444 | 1.090 |
Why?
|
| Aspirin | 2 | 2015 | 63 | 0.930 |
Why?
|
| Risk Factors | 12 | 2025 | 3255 | 0.930 |
Why?
|
| Anticoagulants | 3 | 2023 | 127 | 0.870 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2021 | 53 | 0.840 |
Why?
|
| Embolism | 1 | 2023 | 6 | 0.840 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2023 | 7 | 0.830 |
Why?
|
| Hyperkalemia | 1 | 2023 | 16 | 0.820 |
Why?
|
| Young Adult | 9 | 2025 | 2473 | 0.820 |
Why?
|
| Risk Assessment | 8 | 2025 | 1079 | 0.790 |
Why?
|
| Comorbidity | 8 | 2020 | 564 | 0.780 |
Why?
|
| Diabetic Nephropathies | 1 | 2021 | 25 | 0.740 |
Why?
|
| Aged, 80 and over | 10 | 2020 | 1942 | 0.740 |
Why?
|
| Prevalence | 7 | 2022 | 839 | 0.730 |
Why?
|
| California | 8 | 2025 | 2317 | 0.730 |
Why?
|
| United States | 8 | 2025 | 3891 | 0.730 |
Why?
|
| Health Expenditures | 2 | 2019 | 73 | 0.700 |
Why?
|
| Calcium Channel Blockers | 1 | 2020 | 15 | 0.700 |
Why?
|
| Treatment Outcome | 6 | 2024 | 1170 | 0.690 |
Why?
|
| Health Care Costs | 2 | 2020 | 211 | 0.690 |
Why?
|
| Hemorrhage | 2 | 2023 | 62 | 0.680 |
Why?
|
| Diabetic Retinopathy | 2 | 2018 | 20 | 0.680 |
Why?
|
| Incidence | 5 | 2025 | 1266 | 0.680 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2025 | 165 | 0.650 |
Why?
|
| Adolescent | 8 | 2025 | 3533 | 0.630 |
Why?
|
| Cholesterol, LDL | 2 | 2016 | 112 | 0.620 |
Why?
|
| Antiviral Agents | 1 | 2019 | 100 | 0.610 |
Why?
|
| Hepatitis C | 1 | 2019 | 64 | 0.610 |
Why?
|
| Cost of Illness | 1 | 2018 | 93 | 0.570 |
Why?
|
| Societies, Medical | 1 | 2018 | 71 | 0.560 |
Why?
|
| Guideline Adherence | 1 | 2018 | 152 | 0.520 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 44 | 0.520 |
Why?
|
| Blood Coagulation | 1 | 2015 | 3 | 0.490 |
Why?
|
| Quality of Life | 1 | 2019 | 505 | 0.480 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2015 | 24 | 0.480 |
Why?
|
| Fibrinolytic Agents | 1 | 2015 | 44 | 0.470 |
Why?
|
| Drug Therapy, Combination | 3 | 2021 | 107 | 0.460 |
Why?
|
| Natural Language Processing | 1 | 2015 | 60 | 0.450 |
Why?
|
| Patient-Centered Care | 1 | 2016 | 190 | 0.450 |
Why?
|
| Mass Screening | 2 | 2018 | 671 | 0.450 |
Why?
|
| Quality of Health Care | 1 | 2016 | 279 | 0.450 |
Why?
|
| Managed Care Programs | 1 | 2016 | 309 | 0.440 |
Why?
|
| Predictive Value of Tests | 2 | 2025 | 342 | 0.440 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2016 | 380 | 0.410 |
Why?
|
| Time Factors | 3 | 2025 | 1044 | 0.400 |
Why?
|
| Age Factors | 4 | 2025 | 884 | 0.390 |
Why?
|
| Administration, Oral | 3 | 2023 | 83 | 0.380 |
Why?
|
| Reproducibility of Results | 3 | 2025 | 367 | 0.380 |
Why?
|
| Electronic Health Records | 1 | 2015 | 707 | 0.330 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 1287 | 0.320 |
Why?
|
| Myocardial Infarction | 3 | 2021 | 225 | 0.320 |
Why?
|
| International Normalized Ratio | 2 | 2017 | 21 | 0.260 |
Why?
|
| Osteoarthritis | 2 | 2016 | 15 | 0.260 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2025 | 9 | 0.240 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 538 | 0.240 |
Why?
|
| Case-Control Studies | 2 | 2019 | 1100 | 0.230 |
Why?
|
| Proteinuria | 1 | 2024 | 25 | 0.230 |
Why?
|
| Logistic Models | 2 | 2019 | 884 | 0.220 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 677 | 0.210 |
Why?
|
| Rivaroxaban | 1 | 2023 | 8 | 0.210 |
Why?
|
| Pyridones | 1 | 2023 | 7 | 0.210 |
Why?
|
| Dabigatran | 1 | 2023 | 8 | 0.210 |
Why?
|
| Aldosterone | 1 | 2023 | 2 | 0.210 |
Why?
|
| Potassium | 1 | 2023 | 15 | 0.210 |
Why?
|
| Dementia | 1 | 2025 | 123 | 0.210 |
Why?
|
| Renin-Angiotensin System | 1 | 2023 | 16 | 0.210 |
Why?
|
| Creatinine | 1 | 2023 | 66 | 0.210 |
Why?
|
| Diuretics | 1 | 2022 | 19 | 0.200 |
Why?
|
| Cost-Benefit Analysis | 1 | 2023 | 226 | 0.190 |
Why?
|
| Spironolactone | 1 | 2021 | 6 | 0.190 |
Why?
|
| Angioedema | 1 | 2021 | 6 | 0.190 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2021 | 11 | 0.190 |
Why?
|
| Kidney Diseases | 1 | 2021 | 51 | 0.180 |
Why?
|
| Bioprosthesis | 1 | 2021 | 2 | 0.180 |
Why?
|
| Heart Valves | 1 | 2021 | 3 | 0.180 |
Why?
|
| Heart Valve Diseases | 1 | 2021 | 18 | 0.180 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2020 | 9 | 0.180 |
Why?
|
| Drug Combinations | 1 | 2020 | 43 | 0.170 |
Why?
|
| Coinfection | 1 | 2020 | 31 | 0.170 |
Why?
|
| Recurrence | 1 | 2020 | 165 | 0.170 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2020 | 29 | 0.170 |
Why?
|
| Physicians | 1 | 2021 | 128 | 0.170 |
Why?
|
| Social Class | 1 | 2020 | 117 | 0.170 |
Why?
|
| Cohort Studies | 3 | 2025 | 2526 | 0.160 |
Why?
|
| Drug Monitoring | 2 | 2017 | 18 | 0.150 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 395 | 0.150 |
Why?
|
| Sex Factors | 1 | 2020 | 607 | 0.150 |
Why?
|
| European Continental Ancestry Group | 1 | 2020 | 480 | 0.150 |
Why?
|
| Brain Ischemia | 2 | 2008 | 37 | 0.150 |
Why?
|
| Ethnic Groups | 1 | 2020 | 456 | 0.140 |
Why?
|
| Canada | 1 | 2017 | 70 | 0.140 |
Why?
|
| Testosterone | 1 | 2017 | 23 | 0.140 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 300 | 0.140 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2017 | 32 | 0.130 |
Why?
|
| Influenza, Human | 1 | 2020 | 282 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2019 | 405 | 0.130 |
Why?
|
| Hospitalization | 2 | 2020 | 805 | 0.130 |
Why?
|
| Heart Failure | 1 | 2021 | 404 | 0.120 |
Why?
|
| Information Storage and Retrieval | 1 | 2015 | 15 | 0.120 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 702 | 0.120 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 1155 | 0.110 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 1287 | 0.110 |
Why?
|
| Algorithms | 1 | 2015 | 226 | 0.110 |
Why?
|
| Renal Insufficiency | 1 | 2013 | 12 | 0.110 |
Why?
|
| Causality | 1 | 2013 | 36 | 0.110 |
Why?
|
| Health Maintenance Organizations | 1 | 2015 | 408 | 0.110 |
Why?
|
| Budgets | 1 | 2011 | 5 | 0.090 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2010 | 24 | 0.090 |
Why?
|
| Cost Sharing | 1 | 2010 | 29 | 0.080 |
Why?
|
| Leukoaraiosis | 1 | 2008 | 1 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 263 | 0.070 |
Why?
|
| Remission Induction | 1 | 2025 | 26 | 0.060 |
Why?
|
| Early Detection of Cancer | 1 | 2011 | 529 | 0.060 |
Why?
|
| Sulfonylurea Compounds | 1 | 2025 | 25 | 0.060 |
Why?
|
| Quality Improvement | 1 | 2023 | 190 | 0.040 |
Why?
|
| Orthomyxoviridae | 1 | 2020 | 5 | 0.040 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2020 | 19 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 43 | 0.040 |
Why?
|
| Seasons | 1 | 2020 | 113 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 285 | 0.040 |
Why?
|
| Androgens | 1 | 2017 | 14 | 0.030 |
Why?
|
| Hormone Replacement Therapy | 1 | 2017 | 20 | 0.030 |
Why?
|
| Drug Administration Routes | 1 | 2017 | 5 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2017 | 57 | 0.030 |
Why?
|
| Models, Economic | 1 | 2011 | 17 | 0.020 |
Why?
|
| Reference Values | 1 | 2011 | 86 | 0.020 |
Why?
|
| Probability | 1 | 2011 | 72 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2011 | 76 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2011 | 81 | 0.020 |
Why?
|
| Insurance Claim Review | 1 | 2010 | 55 | 0.020 |
Why?
|
| Propensity Score | 1 | 2010 | 82 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2008 | 2 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2008 | 6 | 0.020 |
Why?
|
| Korea | 1 | 2008 | 9 | 0.020 |
Why?
|
| Arteries | 1 | 2008 | 8 | 0.020 |
Why?
|
| Cerebral Angiography | 1 | 2008 | 5 | 0.020 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2008 | 87 | 0.020 |
Why?
|
| Brain | 1 | 2008 | 48 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 280 | 0.020 |
Why?
|
Concepts
(162)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(17)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->